Clinical Trials Logo
  1. Home
  2. Myeloproliferative Disorders
  3. NCT01144780
  4. Details
NCT01144780 Clinical Trial

Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry

Myeloproliferative Disorders Clinical Trial

Official title:
Investigation of Dysregulated Signaling in Myeloproliferative Disorders Via Multiparameter Phospho-specific Flow Cytometry

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT01144780
Other study ID # IRB-14723
Secondary ID HEMMPD0011SU-070
Status Terminated
Phase
First received
Last updated
Start date September 2009
Est. completion date June 2012

Study information
Verified date April 2020
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this study is to better understand the underlying pathogenetic mechanisms of myeloproliferative disorders (MPDs). We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cells from these patients. This will provide deeper insights into the pathogenesis of MPDs and may lead to the identification of novel targets for therapeutic intervention.

Recruitment information / eligibility
Status Terminated
Enrollment 10
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:Any patient who carries a diagnosis of a myeloproliferative disorder (MPD). Exclusion Criteria:Any patient who is not willing to give consent.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (1)
Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT01684150 - A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Phase 1
Enrolling by invitation NCT01728402 - Pathogenesis of Hematologic Malignancies
Completed NCT00873574 - JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders N/A
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Terminated NCT00578539 - T-Reg Cell Kinetics, Stem Cell Transplant, REGALE N/A
Completed NCT01200498 - Study of SB939 in Subjects With Myelofibrosis Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Completed NCT00569842 - Investigation of the Cylex® ImmuKnow® Assay N/A
Completed NCT00283114 - A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Phase 1
Active, not recruiting NCT04631458 - Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis
Completed NCT01787552 - A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF Phase 1/Phase 2
Terminated NCT02766153 - Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal
Recruiting NCT02320656 - Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 N/A
Terminated NCT00943293 - Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies Phase 1
Completed NCT00038051 - Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies Phase 1
Completed NCT00061581 - Experimental Bone Marrow Transplant Protocol Phase 2
Terminated NCT04631211 - Thrombosomes® in Bleeding Thrombocytopenic Patients Study Phase 2